Scarica l'app Stockscreener
0.3738
2.47%
0.009
Precedente Chiudi:
$0.3648
Aprire:
$0.379
Volume 24 ore:
74,326
Relative Volume:
0.13
Capitalizzazione di mercato:
$15.44M
Reddito:
$9.57M
Utile/perdita netta:
$-43.11M
Rapporto P/E:
-0.3629
EPS:
-1.03
Flusso di cassa netto:
$-49.54M
1 W Prestazione:
+0.65%
1M Prestazione:
-6.55%
6M Prestazione:
-28.81%
1 anno Prestazione:
-84.36%
Intervallo 1D:
$0.365
$0.3799
Intervallo di 1 settimana:
$0.3544
$0.385
Portata 52W:
$0.3421
$5.95
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Confronta SPRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.3738 | 15.44M | 9.57M | -43.11M | -49.54M | -1.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Spruce Biosciences, Inc. (NASDAQ:SPRB) Sees Large Decrease in Short Interest - Defense World
SPRB stock touches 52-week low at $0.36 amid market challenges - Investing.com India
SPRB stock touches 52-week low at $0.36 amid market challenges By Investing.com - Investing.com South Africa
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Congenital Adrenal Hyperplasia Pipeline Analysis 2024: FDA Approvals and Emerging Therapies | Becton, Dickinson and Company, Cook Medical, Cooper Surgical, Smiths Medical, Rocket Medical, CENTOGENE - Barchart
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus PT from Analysts - Defense World
Spruce Biosciences names new interim CMO By Investing.com - Investing.com Canada
Spruce Biosciences names new interim CMO - Investing.com
Congenital Adrenal Hyperplasia Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
SPRB stock touches 52-week low at $0.37 amid market challenges - Investing.com
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
HC Wainwright Has Bullish Estimate for SPRB FY2024 Earnings - Defense World
Spruce Biosciences (NASDAQ:SPRB) Given “Neutral” Rating at HC Wainwright - Defense World
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why - MSN
Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online
Spruce Biosciences’ (SPRB) Neutral Rating Reiterated at Guggenheim - Defense World
Adobe (NASDAQ:ADBE) Cut to “Hold” at TD Cowen - Defense World
FY2024 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World
Citizens Jmp Downgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - Defense World
Needham & Company LLC Reiterates Buy Rating for Recursion Pharmaceuticals (NASDAQ:RXRX) - Defense World
Rigel Pharmaceuticals’ (RIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from Oppenheimer - Defense World
Mizuho Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10 - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from JMP Securities - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Sector Perform” Rating from Royal Bank of Canada - Defense World
Telsey Advisory Group Increases Stitch Fix (NASDAQ:SFIX) Price Target to $6.00 - Defense World
Sirius XM (NASDAQ:SIRI) Earns “Buy” Rating from Guggenheim - Defense World
Wells Fargo & Company Initiates Coverage on Summit Therapeutics (NASDAQ:SMMT) - Defense World
Wells Fargo & Company Reaffirms “Equal Weight” Rating for RxSight (NASDAQ:RXST) - Defense World
Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at JMP Securities - Defense World
SPRB stock touches 52-week low at $0.41 amid market challenges - Investing.com Australia
Clinical Trials News Live Feed - StockTitan
Arnold Schwarzenegger is joining a Fortune 500 company to solve a great problem of his generation - Yahoo Finance
Spruce Biosciences downgraded to Market Perform from Outperform at JMP - MSN
Spruce Biosciences to wind down investment for genetic disorder drug - MSN
JMP Securities Downgrades Spruce Biosciences (SPRB) - MSN
SPRB stock touches 52-week low at $0.41 amid market challenges By Investing.com - Investing.com South Africa
Spruce stock outlook reduced as tildacerfont falls short, company explores alternatives - Investing.com Canada
Oppenheimer Downgrades Spruce Biosciences (SPRB) - MSN
Spruce Biosciences stock downgraded after trial miss By Investing.com - Investing.com Canada
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Benzinga
Spruce Biosciences stock downgraded after trial miss - Investing.com
Spruce Biosciences downgraded to Perform from Outperform at Oppenheimer - TipRanks
Oppenheimer cuts Spruce Biosciences to perform By Investing.com - Investing.com UK
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH - The Bakersfield Californian
Congenital Adrenal Hyperplasia Clinical Trials 2024: EMA, - openPR
Company News for Dec 10, 2024 - Yahoo Finance
Spruce Biosciences Halts CAH Drug Program After Phase 2 Trial Misses Key Endpoint - StockTitan
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spruce Biosciences Inc Azioni (SPRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Charlton Ralph William III | CHIEF MEDICAL OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
106,400 |
0 |
161,773 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 16 '24 |
Option Exercise |
0.00 |
75,750 |
0 |
363,841 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '24 |
Option Exercise |
0.00 |
154,000 |
0 |
356,776 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Option Exercise |
0.00 |
200,700 |
0 |
506,796 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
358,800 |
0 |
466,121 |
| Novo Holdings A/S | 10% Owner |
Mar 21 '24 |
Sale |
0.75 |
465,021 |
350,951 |
2,550,000 |
| Novo Holdings A/S | 10% Owner |
Mar 18 '24 |
Sale |
0.77 |
842,020 |
647,008 |
3,968,000 |
| Novo Holdings A/S | 10% Owner |
Mar 19 '24 |
Sale |
0.76 |
593,000 |
447,715 |
3,375,000 |
| Novo Holdings A/S | 10% Owner |
Mar 20 '24 |
Sale |
0.73 |
359,979 |
264,081 |
3,015,021 |
| Novo Holdings A/S | 10% Owner |
Mar 14 '24 |
Sale |
0.89 |
1,912,316 |
1,698,902 |
4,810,020 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):